Guggenheim Capital LLC Protagonist Therapeutics, Inc Transaction History
Guggenheim Capital LLC
- $12 Billion
- Q4 2024
A detailed history of Guggenheim Capital LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 19,078 shares of PTGX stock, worth $1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
19,078
Previous 7,898
141.55%
Holding current value
$1 Million
Previous $354,000
107.91%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$312 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$303 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$289 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$222 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$175 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.58B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...